Significance of −1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 12655-12664

  Miteva, Lyuba D ^a   Stanilov, Noyko S ^a,b   Deliysky, Tashko S ^c   Stanilova, Spaska A ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

Author keywords

mRNA; rs1800896; Serum; Tumor

Indexed keywords

INTERLEUKIN 10; MESSENGER RNA;

ADULT; ALLELE; ARTICLE; BULGARIAN (PEOPLE); CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; IL10 GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; AGED; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COLORECTAL TUMOR; DISEASE COURSE; GENE EXPRESSION; GENETICS; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMANS; INTERLEUKIN-10; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84919890714     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2589-2     Document Type: Article

References (28)

1. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14.e5.
2. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.
3. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009;27:313–38.
4. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005;78:1043–51.
5. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011;25:2559–72.
6. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22:327–34.
7. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother. 2001;24:392–407.
8. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL-10 gene and further characterization of the 5’ flanking sequence. Immunogenetics. 1997;46:120–8.
9. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1–8.
10. Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med. 2006;32:260–6.
11. Larsson L, Rymo L, Berglundh T. Sp1 binds to the G allele of the-1087 polymorphism in the IL-10 promoter and promotes IL-10 mRNA transcription and protein production. Genes Immunol. 2010;11:181–7.
12. Stanilova S. Cytokine gene polymorphisms in colorectal cancer. In Ettarh R editor. Colorectal cancer biology - from genes to tumor. InTech; 2012. p59-78
13. Zhang YM, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. Genet Mol Res. 2012;11:3389–97.
14. Wilkening S, Tavelin B, Canzian F, et al. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis. 2008;29:1202–6.
15. Cacev T, Radosevic S, Krizanac S, Kapitanovic S. Influence of interleukin-8 and interleukin-10 on sporadic colon cancer development and progression. Carcinogenesis. 2008;29:1572–80.
16. Crivello A, Giacalone A, Vaglica M, et al. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci. 2006;1089:98–103.
17. Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphism in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control. 2009;20:1739–51.
18. Burada F, Dumitrescu T, Nicoli R, Ciurea ME, Rogoveanu I, Ioana M. Cytokine promoter polymorphisms and risk of colorectal cancer. Clin Lab. 2013;59:773–9.
19. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008;7:331–7.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-(delta delta C(T)) method. Methods. 2001;25:402–8.
21. Stanilov N, Miteva L, Deliysky T, Jovchev J, Stanilova S. Advanced colorectal cancer is associated with enhanced IL-23 and IL −10 serum level. Lab Med. 2010;41:159–63.
22. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205–18.
23. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32:23–63.
24. Chichlowski M, Sharp JM, Vanderford DA, Myles MH, Hale LP. Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp Med. 2008;58:534–41.
25. De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer. 1999;86:1936–43.
26. Evans C, Morrison I, Heriot AG, et al. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer. 2006;94:1412–9.
27. Szaflarska A, Szczepanik A, Siedlar M, et al. Preoperative plasma level of IL-10 but not of proinflammatory cytokines is an independent prognostic factor in patients with gastric cancer. Anticancer Res. 2009;29:5005–12.
28. Miteva L, Stanilova S. The combined effect of interleukin (IL)-10 and IL-12 polymorphisms on induced cytokine production. Hum Immunol. 2008;69:562–6.